Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; offers 2025 guidance
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $263.40 -1.44%
EPS Growth %: +2.9%
Financial Fact:
Cost of products sold: 5.49B
Today's EPS Names:
CRMT, PKE, HELE, More
EPS Growth %: +2.9%
Financial Fact:
Cost of products sold: 5.49B
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $2.04, $0.02 better than the analyst estimate of $2.02. Revenue for the quarter came in at $22.52 billion versus the consensus estimate of $22.46 billion.
GUIDANCE:
Johnson & Johnson sees FY2025 EPS of $10.50-$10.70, versus the consensus of $10.60.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
- AeroVironment sets fiscal year 2030 revenue target of $3.5B-$4B
- Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
